DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fareston (Toremifene Citrate) - Summary

 
 



FARESTON SUMMARY

FARESTON (toremifene citrate) Tablets for oral administration each contain 88.5 mg of toremifene citrate, which is equivalent to 60 mg toremifene.

FARESTON is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.


See all Fareston indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Fareston (Toremifene)

Decoding Breast Cancer Risk: BRCA and Beyond
Source: Medscape Hematology-Oncology Headlines [2014.10.16]
Dr Lidia Schapira talks with Dr Leif Ellisen about the controversy of widespread BRCA testing and the practical issues in assessing a woman's risk of developing breast and ovarian cancer.
Medscape Oncology

New treatment target identified for aggressive breast cancer
Source: Breast Cancer News From Medical News Today [2014.10.16]
One of the first-known oncogenes has a protein partner that helps breast cancer proliferate and when it's blocked, so is the cancer, scientists report.

Study finds potential link between breast cancer genes and salivary gland cancer
Source: Breast Cancer News From Medical News Today [2014.10.16]
The risk of developing cancer in a salivary gland might be higher in people with mutations in either of two genes associated with breast and ovarian cancer, according to a new study by researchers...

Healthy Lifestyle May Boost Breast Cancer Survival
Source: MedicineNet Nutrition Specialty [2014.10.16]
Title: Healthy Lifestyle May Boost Breast Cancer Survival
Category: Health News
Created: 10/16/2014 12:00:00 AM
Last Editorial Review: 10/16/2014 12:00:00 AM

Medicare Subsidy Helps Breast Cancer Patients Afford Treatment
Source: MedicineNet Hormone Therapy Specialty [2014.10.15]
Title: Medicare Subsidy Helps Breast Cancer Patients Afford Treatment
Category: Health News
Created: 10/15/2014 12:00:00 AM
Last Editorial Review: 10/15/2014 12:00:00 AM

more news >>

Published Studies Related to Fareston (Toremifene)

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. [2011]
men younger than 80 years... CONCLUSIONS: Toremifene significantly decreased new vertebral fractures in men

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
PURPOSE: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles... CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. [2010.05.15]
BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. We hypothesized that toremifene as compared with tamoxifen given as adjuvant therapy for early stage breast cancer would result in equivalent survival with an improved side effect profile, therefore, providing superior therapeutic efficacy... CONCLUSIONS: Women treated with adjuvant hormonal therapy enjoyed excellent DFS and OS. No significant differences were found between treatment with either tamoxifen or toremifene. Treatment of HR-positive patients with either tamoxifen or toremifene is appropriate. (c) 2010 American Cancer Society.

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. [2010]
gonadotropin-releasing hormone antagonist... CONCLUSIONS: In men with prostate cancer degarelix and leuprolide have similar

more studies >>

Clinical Trials Related to Fareston (Toremifene)

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (FarestonŽ), to the single agent FDA-approved aromatase inhibitor letrozole (FemaraŽ) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (FarestonŽ), is more effective than letrozole (FemaraŽ) in delaying the growth of breast cancer.

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [Terminated]
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (FarestonŽ), is more effective than another approved drug, letrozole (FemaraŽ), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.

The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Active, not recruiting]
The purpose of this study is to determine the effect of toremifene treatment to the MRI findings of the breast in women suffering from premenstrual mastalgia.

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer [Not yet recruiting]
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer [Recruiting]

more trials >>

Reports of Suspected Fareston (Toremifene) Side Effects

Hepatic Function Abnormal (4)White Blood Cell Count Decreased (4)Interstitial Lung Disease (3)Hepatitis Acute (2)Condition Aggravated (2)Bronchiectasis (2)Diarrhoea (2)Respiratory Failure (2)Neoplasm Progression (1)Osteomyelitis (1)more >>


Page last updated: 2014-10-16

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014